Glaukos completes patient enrollment in US NDA Phase 3 Clinical Trials for iDose TR
Glaukos, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient